MBRX MOLECULIN BIOTECH INC US FDA Inspections 8-K Filing 2023 - Clinical Trial Completion Moleculin Biotech, Inc. announced the completion of enrollment in the Phase 2 portion of their clinical trial for the treatment of soft tissue sarcoma lung metastases.Get access to all SEC 8-K filings of the MOLECULIN BIOTECH INC